CommercialCoverageMedium impact
08.00.85t, Tocilizumab and Related Biosimilars for Intravenous Infusion
Independence Blue Cross·Rheumatology, Gastroenterology, Internal Medicine +1 more·Pharmacy
Effective date
Jul 1, 2026
We identified it
Jul 23, 2026
Summary
Policy 08.00.85t establishes coverage guidelines for Tocilizumab and related biosimilars administered intravenously for commercial plans, effective July 1, 2026. The billing team must review this policy to understand prior authorization requirements, covered indications, and applicable HCPCS codes for IV infusion administration to ensure compliant billing and claims processing.
Action Required
Before July 1, 2026: Billing team must obtain and review the complete policy text from the source URL to identify specific HCPCS codes for Tocilizumab and biosimilars, prior authorization requirements, and medical necessity criteria. Update billing system rules, prior authorization workflows, and provider communication materials accordingly. Verify that all Tocilizumab IV infusion claims submitted after July 1, 2026 comply with the new policy requirements to avoid claim denials.